Phapros Tbk. (PEHA)

PT Phapros Tbk

Update terakhir: 15 Juni 2025 17.18 WIB

Rp 364

18,00(5,20%)

CLOSED
Ringkasan Pasar
  • Harga Pasar: Rp 364
  • Volume Perdagangan: Rp 2.287.800
  • Kapitalisasi Pasar: Rp 305.760.010.240
  • Mata Uang: IDR
  • Pasar: id_market
Rasio dan Dividen
  • Dividend Yield: -%
  • Dividend Rate: Rp -
  • Price to Book: 0,82
  • Forward P/E: -
  • Trailing P/E: -
  • EPS Tahun Ini: Rp -311,00
  • EPS Perkiraan: Rp -
Teknikal & Statistik Perdagangan
  • Bid: Rp 364,00
  • Ask: Rp 366,00
  • Bid Size: 0,00
  • Ask Size: 0,00
  • Volume Rata-rata 10 Hari: 1.855.750
  • Volume Rata-rata 3 Bulan: 377.156
  • Book Value: Rp 445,24
  • Fifty Day Average: Rp 283,36
  • Two Hundred Day Average: Rp 319,60
  • 52 Week Range: 260.0 - 424.0
  • 52 Week High: Rp 424,00
  • 52 Week Low: Rp 260,00
  • Regular Market Open: Rp 350,00
  • Regular Market Previous Close: Rp 346,00
  • Regular Market Day High: Rp 398,00
  • Regular Market Day Low: Rp 334,00
  • Earnings Call Start: -
  • Earnings Call End: -
  • Earnings Timestamp: -
Informasi Perusahaan & Sektor

Sektor

Healthcare

Industri

Drug Manufacturers - Specialty & Generic

Alamat Perusahaan

Menara Rajawali Lt. 17

Jl. Dr. Ide Anak Agung Gde Agung Kuningan

Jakarta Selatan

12950

Ringkasan Bisnis

PT Phapros Tbk, together with its subsidiaries, operates in the pharmaceutical industry in Indonesia. The company operates through Ethical; Over the Counter (OTC) Drugs; Ethical; Generic Drugs Bearing; and Toll-in Manufacturing segments. It offers OTC drugs, including Antimo Anak, Livron B Plek, Noza, Hemorogard, Bioron, and others. The company also provides generic drug products for government institutions and hospitals, as well as produces drugs for other pharmaceutical industries; and offers medical devices, as well as branded/ethical prescription drugs to hospitals, pharmacies, and other healthcare institutions. It exports its products. The company was founded in 1954 and is headquartered in Jakarta Selatan, Indonesia. PT Phapros Tbk is a subsidiary of PT Kimia Farma Tbk.